GlassScriptPhysician profile
Sassan Soltani
NPI 1649244104
$10,729.41
in general payments reported to CMS, 2019-2025
36 companies · $1,927 in 2025
The $1,927 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,499 · 2020: $632 · 2021: $1,281 · 2022: $1,906 · 2023: $1,719 · 2024: $1,766 · 2025: $1,927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,412.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,340.22 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $1,309.25 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $695.31 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $614.03 | 2019-2024 | Trulance |
| Ardelyx, INC. | $478.40 | 2022-2025 | Ibsrela |
| Pfizer INC. | $390.52 | 2019-2025 | |
| Madrigal Pharmaceuticals | $259.55 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $235.69 | 2023-2025 | Rebyota |
| Gilead Sciences, INC. | $189.54 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $178.96 | 2019-2024 | Dificid |
| Qol Medical, LLC | $175.68 | 2019-2025 | Sucraid |
| Celgene Corporation | $158.15 | 2022-2024 | Zeposia |
| Lilly USA, LLC | $148.75 | 2024-2025 | Omvoh |
| Novo Nordisk INC | $147.91 | 2025 | Wegovy |
| Aimmune Therapeutics, INC. | $146.65 | 2024-2025 | Vowst, Zenpep |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $128.94 | 2021-2023 | Talicia |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2022 | |
| Intercept Pharmaceuticals, INC. | $123.77 | 2019-2024 | |
| Nestle Healthcare Nutrition INC. | $105.71 | 2020-2023 | |
| Endogastric Solutions, INC | $80.40 | 2019 | |
| Erbe USA INC | $74.21 | 2019 | |
| Genzyme Corporation | $71.42 | 2022-2024 | |
| Medtronic, INC. | $71.35 | 2021-2024 | Gi Genius |
| Phathom Pharmaceuticals, INC. | $61.95 | 2024 | Voquezna |
| Celltrion USA INC. | $60.42 | 2024-2025 | Vegzelma |
| Covidien LP | $50.85 | 2019 | |
| Almirall LLC | $47.63 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $47.25 | 2021 | |
| Capsovision, INC. | $35.65 | 2023 | Capsocam Plus |
| Ipsen Biopharmaceuticals, INC | $30.17 | 2024 | Bylvay |
| Shionogi INC | $27.65 | 2020 | |
| Epi Health, LLC | $27.30 | 2020 | |
| Ucb, INC. | $25.95 | 2019 | |
| Biofrontera INC. | $24.91 | 2022 | |
| Shire North American Group INC | $22.27 | 2019 | |
| Organon LLC | $18.00 | 2023 | Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sassan Soltani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.